Psychosemiotics and Information Literacy Instruction: Identifying Signways in Library Tutorials

See presentation description

Technology in Practice: Educators Training in Reading Clinics/Literacy Labs

In-depth interviews of graduates of reading clinic/literacy lab courses (n=28) focused on the transfer of technology use for literacy assessment and instruction from clinic/lab to classrooms/schools. Analysis of the interviews showed that technologies are being used in both clinic/lab and in K-12 settings in a variety of ways: 1) technologies for literacy assessment, 2) technologies that replace instruction by a teacher, 3) technologies that support teacher-directed instruction, 4) assistive technologies—for students with severe difficulties, 5) student-directed independent uses of technology, and 6) technologies used for planning/management. Implications for inclusion of technologies in literacy course work are discussed

Clinical experience with the use of ferric citrate as a phosphate binder in pediatric dialysis patients

BackgroundFerric citrate, an iron-based phosphate binder, has been shown to improve both hyperphosphatemia and iron deficiency in adult chronic kidney disease patients, but its use in the pediatric dialysis population has not been described.MethodsThis is a retrospective analysis of 11 unselected pediatric dialysis patients who received ferric citrate as a phosphate binder between 2015 and 2017. Time-averaged laboratory values were compared pre- and post-ferric citrate initiation using the Wilcoxon signed-rank test.ResultsThe median age of this cohort was 13 years old (range 4-17 years old). Five patients were on hemodialysis, and six patients were on peritoneal dialysis. The median duration of ferric citrate therapy was 214 days (range 39-654 days), with a median time-averaged ferric citrate dose of 3.5 tablets per day (range 1.5-8.4 tablets per day). Compared to the pre-ferric citrate period, ferric citrate treatment was associated with decreased serum phosphate (6.5 to 5.2 mg/dl, p = 0.014), decreased phosphate age-related standard deviation score (SDS) (2.3 to 0.9, p = 0.019), increased transferrin saturation (26 to 34%, p = 0.049), increased ferritin (107 to 230 ng/ml, p = 0.074), and maintenance of hematocrit.ConclusionsIn pediatric dialysis patients, ferric citrate may be able to concurrently lower phosphate levels and treat iron deficiency. However, larger studies are needed to further evaluate safety and efficacy in the pediatric chronic kidney disease population